Klegerman M E, Zeunert P L, Lou Y, Devadoss P O, Groves M J
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago.
Cancer Invest. 1993;11(6):660-6. doi: 10.3109/07357909309046938.
Bacillus Calmette-Guérin (BCG) inhibited adherence of S180 mouse sarcoma cells and WI38 human diploid fibroblasts to the polystyrene substratum of 24-well cluster dishes in a dose-dependent manner. This property was retained by washed or heat-killed bacilli, but not by the vaccine filtrate or by the spent bacterial culture medium. Adhesion of bacilli to nonadherent S180 cells was demonstrated by light and scanning electron microscopy, but was not seen after trypsinization of adherent cells, indicating that bacilli bind to cell-surface adhesins. Preincubation of bacilli with human fibronectin abolished their ability to inhibit S180 adherence, suggesting that the phenomenon may be mediated by interaction of bacilli with cell-surface fibronectin. Fibronectin pretreatment of the bacteria also decreased their inhibition of S180 tumor growth in vivo, indicating that this mechanism may be at least partly responsible for BCG vaccine's observed antineoplastic activity.
卡介苗(BCG)以剂量依赖的方式抑制S180小鼠肉瘤细胞和WI38人二倍体成纤维细胞黏附于24孔培养板的聚苯乙烯基质上。洗涤过的或经热灭活的杆菌保留了这一特性,但疫苗滤液或用过的细菌培养基则没有。通过光学显微镜和扫描电子显微镜证实了杆菌与未黏附的S180细胞的黏附,但在对黏附细胞进行胰蛋白酶消化后未观察到这种黏附,这表明杆菌与细胞表面黏附素结合。杆菌与人纤连蛋白预孵育后,其抑制S180黏附的能力丧失,这表明该现象可能是由杆菌与细胞表面纤连蛋白的相互作用介导的。对细菌进行纤连蛋白预处理也降低了其对体内S180肿瘤生长的抑制作用,表明该机制可能至少部分地解释了BCG疫苗所观察到的抗肿瘤活性。